For example, OMS721, a monoclonal antibody targeting MASP-2, was recently designated breakthrough therapy status for IgAN treatment; Eculizumab, a C5 inhibitor, has been used in recurrent61 and progressive62, 63 IgAN; and factor D inhibitors are in clinical trials for C3 glomerulopathy.64 Here, MASP2 is linked to complement 3 glomerulopathy.